Bill > HB0390

This bill establishes a clinical study to research the safety and effectiveness of psychedelic-assisted therapy for eligible veterans who have treatment-resistant PTSD, meaning they have not responded to other treatments. The study will be conducted by the Huntsman Mental Health Institute and will be funded by legislative appropriations and any gifts or grants received. The bill defines key terms such as "psychedelic drug" (including MDMA, 5-methoxy-N,N-dimethyltryptamine, and psilocybin), "psychedelic-assisted therapy" (which involves administering a psychedelic drug in a controlled setting alongside psychotherapy), and "treatment-resistant PTSD." The Huntsman Mental Health Institute must comply with federal regulations, including FDA approval and DEA registration, and develop detailed protocols for the study's design, drug administration, safety monitoring, and psychotherapy fidelity. The study must begin by January 1, 2027, if sufficient funding is secured, and the institute is required to report its findings to the Health and Human Services Interim Committee. The bill also includes a repeal date of July 1, 2032, for the section establishing this clinical study, and it takes effect on May 6, 2026.

Health and Social Services

https://le.utah.gov/~2026/bills/static/HB0390.html